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Remote ischemic postconditioning (RIPostC) is a promising therapeutic intervention that could be administered as an alternative
to cooling in cases of perinatal hypoxia-ischemia (HI). In the current study we hypothesized that RIPostC in the piglet model
of birth asphyxia confers protection by reducing nitrosative stress and subsequent nitrotyrosine formation, as well as having an
effect on glial immunoreactivity. Postnatal day 1 (P1) piglets underwent HI brain injury and were randomised to HI (control) or
HI + RIPostC. Immunohistochemistry assessment 48 hours after HI revealed a significant decrease in brain nitrotyrosine deposits
in the RIPostC-treated group (𝑝 = 0.02). This was accompanied by a significant increase in eNOS expression (𝑝 < 0.0001) and
decrease in iNOS (𝑝 = 0.010), with no alteration in nNOS activity. Interestingly, RIPostC treatment was associated with a significant
increase in GFAP (𝑝 = 0.002) and IBA1 (𝑝 = 0.006), markers of astroglial and microglial activity, respectively. The current
study demonstrates a beneficial effect of RIPostC therapy in the preclinical piglet model of neonatal asphyxia, which appears to
be mediated by modulation of nitrosative stress, despite glial activation.
1. Introduction
Hypoxic-ischemic encephalopathy (HIE) occurs after intra-
partum asphyxia [1] and is responsible for 23% of neona-
tal deaths worldwide [2]. Hypothermia therapy has been
established as standard clinical care for infants diagnosed
with moderate to severe neonatal encephalopathy (NE) in
the developed world. Cooling started within six hours of
birth ameliorates secondary energy failure and cell death,
significantly lowering the risk of death and severe disability
in treated infants [3, 4]. In the UK, 45% of infants have
adverse outcome after HIE despite cooling, with 25% dying
and 20% developing cognitive cerebral palsy and other
life-long debilitating conditions [5]. Adjunct therapies for
hypothermia are needed to enhance overall protection and
improve outcome. In low and mid resource settings where
cooling is not routine, alternative therapiesmay be important.
The developing neonatal brain is particularly vulnerable
to oxidative stress because free-radical scavenging systems
have not yet matured, resulting in insufficient synthesis of
antioxidant enzymes/scavengers following injury [6]. The
free-radical nitric oxide (NO) is an ubiquitous neurotrans-
mitter and an important signalling molecule with multiple
functions within the CNS. In the brain, NO is synthetized
from arginine, nicotinamide adenine dinucleotide phosphate
(NADPH), and oxygen by three distinct isoforms of NO syn-
thase (NOS). Neuronal NOS (nNOS) is a calcium-dependent
enzyme that is upregulated during ischemia. Resulting NO
production reacts with ROS to produce several radicals
detrimental to neuronal survival [7–12]. Inducible NOS
(iNOS) is a calcium-independent enzyme associated with
inflammatory markers and can be produced by macrophages
and various other cells under pathological conditions. Like
nNOS, iNOS has also shown a link with neuronal loss [6, 8, 9,
11, 13]. Calcium-dependent endothelial NOS (eNOS) enzyme,
unlike nNOS and iNOS isoenzymes, is thought to be protec-
tive under ischemic conditions, potentially as a result of its
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vasodilating effect and subsequent improvement in cerebral
perfusion [9, 11, 14–17]. Oxidative stress results in excessive
production of NO within different brain regions. NO then
combines with superoxide radicals to produce peroxynitrite
[18, 19]. Nitrotyrosine is a product of tyrosine nitration from
peroxynitrite, and its formation in proteins is an indicator
of cell damage. This has been shown both in animal models
as well as in clinical cases of brain perinatal asphyxia [11,
20–23]. In addition to directly causing apoptotic cell death
in the brain, oxidative stress products induce a profound
inflammatory response characterised by neuroglial activation
[24]. Reactive oxygen species and important transcription
factors such as the inflammatory and antiapoptotic NF-𝜅B
[11] stimulate astrocytes and microglia, which respond by
secreting a number of proinflammatory cytokines such as
interleukin 6 (IL-6) and tumour necrosis factor alpha (TNF-
𝛼) [19, 25].
RIPostC is the application of “brief intermittent cycles
of ischemia alternating with reperfusion” [26] in the limbs
after an ischemic insult. RIPostC has been shown to reduce
cerebral ischemia-induced infarct size and neuronal apopto-
sis in rats [27] and could be similarly effective in neonates.
Whilst the underlying neuroprotective mechanism is yet
to be understood, RIPostC may interfere with apoptotic
pathways by reducing oxidative stress to indirectly inhibit
NF-𝜅Bactivity [27]. In addition, animalmodels ofmyocardial
injury have shown attenuation of nitrosative stress following
postconditioning [28].We have previously shown in a neona-
tal piglet model that RIPostC treatment confers white matter
protection [29]. In this study we aimed to investigate whether
RIPostC protection was associated with changes in oxidative
stress, which are also linked to glial activation/inflammation.
2. Materials and Methods
2.1. Animal Experiments and Surgical Preparation. All animal
experiments were approved by the Ethics Committee of the
University College London and carried out by licensed per-
sonnel in concordance with the UK Home Office Guidelines
[Animals (Scientific Procedures) Act, 1986] and in compli-
ance with the ARRIVE guidelines. Large white newborn
female piglets at postnatal day 1 (P1) were sedated, anes-
thetized, and surgically prepared as described previously [30–
33]. In brief, animals were sedated with intramuscular mida-
zolam (0.2mg/kg) and anaesthetised with isoflurane (4% v/v)
to facilitate tracheostomy and intubation and maintained
with 3% during surgery, 2% v/v otherwise. Mechanical venti-
lationwas titrated to ensure partial arterial pressure of oxygen
(PaO
2
) at 8–13 kPa and carbon dioxide (PaCO
2
) at 4.5–
6.5 kPa. After the airway was secured, both common carotid
arteries were isolated at the level of the fourth cervical verte-
bra and encircled by remotely controlled vascular occluders
(OC2A, In Vivo Metric). An umbilical arterial catheter was
inserted to enable continuous monitoring of heart rate (HR),
mean arterial blood pressure measurement, and arterial
blood extraction to measure PaO
2
, PaCO
2
, pH, electrolytes,
glucose (3–10mmol/L), and lactate (I-Stat, Abbott Labora-
tories, Maidenhead, UK). Mean arterial blood pressure was
maintained at approximately 40mmHg using saline boluses
and infusions of inotropes (dopamine and dobutamine
5–20𝜇g/kg/min each). Hyperglycemia (>10mmol/L) was
treated by substituting 10% with 5% dextrose; Hyperglycemia
(>20mmol/L) was treated by substituting 5% dextrose for
saline. Hyperkalemia (K+ > 7mmol/L) was treated with
4mcg/kg salbutamol (10mcg/mL) through the umbilical
venous catheter over 10 minutes. Metabolic acidosis (base
excess < −10) was corrected with sodium bicarbonate
(8.4%wt/vol). All animals received continuous physiological
monitoring (SA Instruments, Stony Brook, NY) and exten-
sive life support throughout experimentation. Arterial lines
were maintained by infusing 0.9% saline solution (1mL/h);
heparin sodium (1 IU/mL) was added to prevent blockage.
After surgery, and before securing the piglets in a prone
position in an acrylic pod with their heads immobilized, the
purpose built postconditioning device was placed over both
inguinal canals and strapped securely diagonally across the
inguinal region with an inflatable bladder placed underneath
for further fixation. To assess limb blood perfusion during
and after RIPostC, a separate pulse oximeter was secured to
the right hind limb, while a laser Doppler assessed perfusion
on the left hind limb. An additional pulse oximeter was
attached to the right fore limb to measure systemic oxygen
saturation [29].
2.2. Cerebral Hypoxia-Ischemia. A 70 × 50mm, elliptical
transmit/receive surface coil tuned for 31P signal acquisition
was secured to the head and the animal placed into the
bore of a 9.4 Tesla Agilent spectrometer. Whilst in the MRS
system, transient HI was induced by remote occlusion of
common carotid arteries using inflatable vascular occluders
and reducing fractional inspired oxygen (FiO
2
) to 6% v/v.
During HI, the 𝛽-nucleotide trisphosphate (NTP) was con-
tinuously monitored using in-house Matlab (Mathworks)
software. When 𝛽-NTP fell to 40% baseline value, FiO
2
was titrated to maintain 30–40% 𝛽-NTP for 12.5 minutes.
At the end of insult, the occluders were deflated and FiO
2
normalized. This leads to loss of neurons and TUNEL and
caspase 3 positive cell death as well as microglial activation
[31–33].
2.3. Experimental Groups. Following resuscitation, piglets
were randomised into two groups: HI (𝑛 = 8) and HI +
RIPostC (𝑛 = 8). Resuscitation after the end of transient
HI was taken at time point zero. Piglets were maintained
at their target rectal temperature of 38.5 ± 0.5∘C using a
warmed water mattress. RIPostC was administered with a
purpose built device fitted after surgery around the piglet
hind limbs andwas induced by inflating the device to occlude
the femoral artery and then deflating it induced reperfusion.
Immediately after resuscitation, piglets underwent 4 cycles
of 10 minutes ischemia followed by 10 minutes reperfusion
in both hind limbs [29]. In the RIPostC study, cerebral
HI resulted in similar insult severity between both groups;
however, white matter lactate/N acetyl aspartate was signifi-
cantly reduced in RIPostC-treated animals 48 hours after HI,
and NTP/epp was substantially higher in the treated group
[29].
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2.4. Brain Histology. Forty-eight hours after HI, piglets
were euthanized with pentobarbital. The brains were fixed
via cardiac perfusion with phosphate-buffered saline (PBS)
followed by cold 4% paraformaldehyde/PBS, dissected out
and postfixed at 4∘C in 2% paraformaldehyde for 9 days.
Coronal slices (5mm thickness) of the whole right hemi-
sphere were embedded in paraffin wax and sectioned to
8 𝜇m thickness. For each animal, 2 sections (bregma 00
and −2.0) were stained issuing immunohistochemistry and
12 different brain regions were blindly examined. To assess
nitrosative stress, adjacent brain sections were stained for
nitrotyrosine, inducible NO synthase (iNOS), neuronal NO
synthase (nNOS), and endothelial NO synthase (eNOS),
respectively. To assess glial activation, sections were also
stained for glial fibrillary acidic protein (GFAP) and ionized
calcium-binding adaptor molecule 1 (IBA1).
The brain sections were treated as previously described
[32]. In brief, sections were rehydrated followed by heat
treatment for antigen retrieval. Sections were then blocked
with 5% goat serum (Sigma-Aldrich, USA) for 30 minutes
and incubated overnight with nitrotyrosine (1 : 4000, BD Bio-
sciences, UK), iNOS (1 : 200, Novus Biologicals, UK), nNOS
(1 : 200, Bioss, UK), eNOS (1 : 1000, BD Biosciences, UK),
IBA1 (1 : 2000 Wako, Japan), GFAP (1 : 1000 EMD Millipore,
USA), or GFAP (1 : 5000, eBiosciences, USA). Sections were
incubated with biotinylated secondary antibody (1 : 250).The
staining was visualized using ABC (Vector Laboratories,
UK) and DAB (Thermo Scientific, USA). The sections were
counterstained with haematoxylin before being dehydrated
in graded alcohol and xylene and mounted with Depex
(Leica Biosystems, USA). Na¨ıve controls were stained for the
aforementioned markers to demonstrate baseline levels.
For fluorescence double labelling, sections were stained
as described above. Nitrotyrosine colabel with eNOS and
GFAP sections were incubated with both primary antibod-
ies overnight and then incubated with a biotin-conjugated
donkey anti-rabbit Ig and an AlexaFluor488-conjugated goat
anti-mouse Ig antibody, followed by tertiary AlexaFluor488-
conjugated donkey anti-goat Ig antibody, and Texas Red-
Avidin (Vector Laboratories, USA, 1 : 1000) was added. For
nitrotyrosine with iNOS, nNOS, and IBA1, sections were
incubated with primary, secondary, and tertiary antibodies
for nitrotyrosine only, blocked with goat and donkey serum
(Sigma-Aldrich, USA) and then incubated with antibodies
for the second marker. In both protocols, sections were
counterstained with DAPI for nuclear visualisation following
incubation with the tertiary antibody and then stored in the
dark at 4∘C.
2.5. Data Analysis. For each animal and section, 12 brain
regions were assessed blindly (Figure 2). For nitrotyrosine,
nNOS, iNOS, and eNOS, 3 fields per regionwere scored using
a light microscope at ×20 magnification. The semiquanti-
tative scoring system used is described in Table 1 (adapted
from [34, 35]). For GFAP and IBA1 assessment was carried
out using quantitative thresholding image analysis (adapted
from Rahim et al., 2012 [36]). 10 nonoverlapping images (per
region) were captured using a live video camera (Nikon,
DS-Fi1) mounted onto a Nikon Eclipse E600 microscope at
Table 1: Brain semiquantitative score system.
Score Staining % positive cells
0 None 0
1 Weak ≤25
2 Moderate ≥25–≤75
3 Severe ≥75
×40 magnification. Immunoreactivity was determined using
Image-Pro Plus (MediaCybernetics, Silver Spring,MD,USA)
with the threshold setting kept constant for all subsequent
images for each respective antibody.
2.6. Statistical Analysis
2.6.1. Comparison of Treatment Groups. For each study and
for each measurement type, three separate field (nitrotyro-
sine, iNOS, eNOS, and NOS) and ten separate field (GFAP
and IBA1) results were averaged for each subject for each
region. Analysis of variance (ANOVA) was performed on the
mean data (overall brain effect) with terms for Treatment,
Region, and the interaction between Treatment and Region
fitted in the model. The significance (𝑝 value) for the Treat-
ment effect was assessed to see whether there was evidence of
a difference between the overall treatment group means.
2.6.2. Correlation betweenMeasurements. For both treatment
groups, the correlation between the different measurements
was assessed. A matrix plot which shows a grid of𝑋𝑌 scatter
plots for each possible pairing of two of the measurements
was produced with each of the points on the plot being the
average values of𝑋 and 𝑌 for a particular subject and region.
The points in the plot have been identified by the treatment
group for the subject and linear regression lines have been
plotted so as to assess the strength of a linear relationship
between the two measurements. Correlation coefficients 𝑅
have been tabulated for each pairing of variables for each
study.
Results are presented as mean (±SD), and statistical
significance was assumed for 𝑝 < 0.05.
3. Results
3.1. Formation of Nitrotyrosine Deposits. Nitrotyrosine is a
reaction product of peroxynitrite, a powerful oxidising and
nitrating agent that damages lipids, proteins, and DNA [19,
37]. In human neonates, nitrotyrosine deposits are present
after perinatal asphyxia [23] and positive staining of the
neuronal cytoplasm is a marker of cell damage, oxidative
stress, and inflammation that correlates with severity of
brain damage and poor outcomes [38]. However, little to no
nitrotyrosine deposits are found in healthy organs [39] or
in an infant human case control of spinal muscular atrophy
without HIE [23]. In the current study, 48 hours after HI
insult, nitrotyrosine staining was seen in all brain regions
in both HI (controls) and HI + RIPostC groups. Overall
semiquantitative scoring assessment showed that levels of
nitrotyrosine deposits 48 hours after HI was significantly
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Figure 1: RIPostC decreases nitrotyrosine deposits in the brain 48 hours after HI. (a) Representative nitrotyrosine staining from the
hippocampus at 48 hours afterHI inHI alone (upper panel) andHI + RIPostC (lower panel). Na¨ıve brain has also been stained to demonstrate
the lack of nitrotyrosine deposits in health tissue (left panel). (b) Mean nitrotyrosine scores across multiple brain regions in HI alone and
in RIPostC-treated piglets. (c) Overall brain nitrotyrosine scores 48 hours after HI. Data are expressed as mean ± SEM in ANOVA, 𝑛 = 8
per group, and ∗𝑝 < 0.05. dCTX1–3 = dorsal cortex 1–3; mCTX = midtemporal cortex; PYR = pyriform cortex; THAL = thalamus; Caudt =
caudate; PTMN = putamen; IC = internal capsule; PvWM = periventricular white matter.
reduced across the entire brain hemisphere in RIPostC-
treated animals compared to controls (from 1.1 ± 0.3 to 0.2 ±
0.2, 𝑝 = 0.02) (Figure 1(c)).
3.2. Production ofOxidative Stress Biomarkers (NOSynthases).
The presence of nitrotyrosine is regarded as a marker of per-
oxynitrite and suggestive of a role of NO toxicity (nitrosative
stress) in HI brain injury. To determine the potential source
of nitrotyrosine, NOS –nNOS, iNOS, and eNOS were sub-
sequently assessed using the same semiquantitative scoring
system performed in the nitrotyrosine assessment.
3.2.1. Neuronal Nitric Oxide Synthase Expression (nNOS).
Assessment of nNOS expression showed no significant differ-
ence in nNOS expression in the HI + RIPostC group versus
HI alone (Figure 2(c)).
3.2.2. Inducible Nitric Oxide Synthase Expression (iNOS). We
observed significantly less iNOS expression across the brains
of theHI + RIPostC group than in theHI control group (from
0.8 ± 0.3 to 0.4 ± 0.2, 𝑝 = 0.010) (Figure 2(f)).
3.2.3. Endothelial Nitric Oxide Synthase Expression (eNOS).
There was a significant overall brain increase in eNOS
expression in the HI + RIPostC group compared to the HI
control group (from 0.4 ± 0.2 to 1.2 ± 0.3, 𝑝 < 0.0001)
(Figure 2(i)).
3.3. Glial Activation. To determine whether neuroprotection
was associated with glial activation, sections were stained
for markers of astrogliosis (GFAP) and microglial activation
(IBA1). Analysis of these stainings consisted of quantitative
threshold analysis of 10 nonoverlapping images per assessed
brain region and immunoreactivity determined using Image-
Pro Plus software.
3.3.1. Microglia. The overall level of microglial activation was
significantly higher in RIPostC-treated animals in compar-
ison to controls (from 2.8 ± 0.8 to 4.9 ± 1.7, 𝑝 = 0.006)
(Figure 3(c)).
Table 2: Correlation matrix between nitrotyrosine deposits and
markers of NOS and glia activity.
RIPostC eNOS GFAP IBA1 iNOS Nitrotyrosine nNOS
eNOS 0.22 0.06 −0.29 −0.30 −0.16
GFAP 0.05 −0.20 −0.18 −0.07
IBA1 0.01 −0.12 −0.05
iNOS 0.46 0.36
Nitrotyrosine 0.31
3.3.2. Astrocytes. Assessment of astrocyte activation (GFAP)
showed overall significant increase in the RIPostC group
versus control (from 9.0 ± 2.6 to 13.3 ± 3.4, 𝑝 = 0.002)
(Figure 3(f)).
3.4. Correlation of Nitrotyrosine, Oxidative Stress Biomarkers,
and Glial Activation. Our results showed that nitrotyro-
sine deposits, expression of NO synthases microglia, and
astroglial activation were affected by RIPostC treatment.
Therefore, we assessed potential histological correlations
between nitrotyrosine deposits and each of the NOS and glial
markers used. Overall, nitrotyrosine deposits correlated pos-
itively with nNOS (𝑟 = 0.31) and iNOS (𝑟 = 0.46) expression
and correlated negatively with eNOS expression (𝑟 = −0.30).
Although moderate 𝑅2 values indicate that these correlations
are not very strong, the consistent effect suggests a reasonable
link. There was no correlation between nitrotyrosine and
IBA-1 (𝑟 = −0.12) and GFAP (𝑟 = −0.18) markers (Table 2).
3.5. Colocalization of Nitrotyrosine and NOS in Different Cell
Types. Colabeling of nitrotyrosine with different cell types as
well as NOS showed that nitrotyrosine deposits were present
mostly in neuronal cells of both treatment groups but to a
greater extent in HI animals (Figures 4(a)-4(b)). Nitrotyro-
sine deposits were also identified in some endothelial cells of
HI control animals (Figure 4(g)) as well as nNOS (Figures
4(i)-4(j)) and iNOS positive cells in both groups (Figures
4(k)-4(l)). Some nitrotyrosine deposits were also present
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Figure 2: Effect of RIPostC treatment on nitric oxide synthases. (a–c) nNOS levels remain unaffected by RIPostC treatment 48 hours after
HI. (a) Representative nNOS staining from the hippocampus at 48 hours after HI in HI alone (upper panel) and HI + RIPostC (lower panel).
(b) Mean nNOS scores across multiple brain regions in HI alone and in RIPostC-treated piglets. (c) Overall brain nNOS scores 48 hours
after HI. (d–f) RIPostC treatment significantly reduced overall iNOS levels in the brain 48 hours after HI. (d) Representative micrographs
of iNOS staining from the hippocampus at 48 hours after HI in HI alone (upper panel) and HI + RIPostC (lower panel). (e) Mean iNOS
scores across multiple brain regions in HI alone and in RIPostC-treated piglets. (f) Overall brain iNOS scores 48 hours after HI showing
significant reduction in iNOS semiquantitative scoring for the RIPostC-treated group (𝑝 = 0.010). (g–i) RIPostC treatment was associated
with a significant increase in endothelium-derived NO 48 hours after HI injury. (g) Representative eNOS immunohistochemistry from the
hippocampus at 48 hours after HI in HI alone (upper panel) and HI + RIPostC (lower panel). (h) Mean eNOS scores across multiple brain
regions in HI alone and in RIPostC-treated piglets. (i) Overall significant increase in brain eNOS semiquantitative scores in RIPostC-treated
piglets 48 hours after HI. (a, d, g) For comparison, naı¨ve tissue is shown in the left column. Data are expressed as mean ± SEM in ANOVA,
𝑛 = 8 per group, and ∗𝑝 < 0.05. dCTX1–3 = dorsal cortex 1–3; mCTX = midtemporal cortex; PYR = pyriform cortex; THAL = thalamus;
Caudt = caudate; PTMN = putamen; IC = internal capsule; PvWM = periventricular white matter.
in microglia IBA1-stained cells of RIPostC-treated animals
(Figures 4(c)-4(d)) but not in astroglia (Figures 4(e)-4(f)).
iNOS marker was identified in neurons (Figures 4(m)-4(n))
and astrocytes (Figures 4(q)-4(r)) of both HI and RIPostC-
treated animals, as well as in microglia of RIPostC group
(Figure 4(p)). However, no iNOS deposits were observed in
endothelial cells (Figures 4(s)-4(t)).
4. Discussion
Our results demonstrate that RIPostC treatment has a sig-
nificant association with decrease in nitrotyrosine deposits
in the brain, as well as iNOS. Conversely, eNOS was sig-
nificantly upregulated, with also a substantial increase in
IBA1 and GFAP glial markers, suggesting that RIPostC may
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Figure 3: RIPostC-treated animals have increased glial activation. (a–c) IBA1 quantitative thresholding analysis revealed significant increase
inmicroglial IBA1+ staining in the HI + RIPostC group 48 hours after HI. (a) Representative IBA1 staining from the hippocampus at 48 hours
after HI in HI alone (upper panel) and HI + RIPostC (lower panel). (b) Mean IBA1 quantitative thresholding analysis across multiple brain
regions in HI alone and in RIPostC-treated piglets. (c) Overall IBA1 immunoreactivity was significantly increased in the RIPostC-treated
group when compared to HI alone piglets (𝑝 = 0.006). (d–f) RIPostC treatment significantly increased GFAP+ astrocytes 48 hours after HI.
(d) Representativemicrographs ofGFAP immunohistochemistry from the hippocampus at 48 hours afterHI inHI alone (upper panel) andHI
+ RIPostC (lower panel). (e) Mean GFAP quantitative thresholding analysis across multiple brain regions in HI alone and in RIPostC-treated
piglets. (f) RIPostC treatment resulted in an overall significant increase in GFAP+ astrocyte immunoreactivity 48 hours after HI (𝑝 = 0.002).
(a, d) Na¨ıve comparative controls are shown on the left panel. Data are expressed as mean ± SEM in ANOVA, 𝑛 = 8 per group, and ∗𝑝 < 0.05.
dCTX1–3 = dorsal cortex 1–3; mCTX =midtemporal cortex; PYR = pyriform cortex; THAL = thalamus; Caudt = caudate; PTMN = putamen;
IC = internal capsule; PvWM = periventricular white matter.
work through reduction in oxidative/nitrosative stress despite
increased glial activation.
4.1. Remote Ischemic Postconditioning Reduces Nitrotyrosine
Deposits. Several neurological conditions are associated with
formation of nitrotyrosine deposits, which in turn is associ-
ated with brain tissue damage. Groenendaal et al. described
the presence of nitrotyrosine deposits, particularly in the
thalamus and inferior olives of 22 full-term infants [23], as
well as in the spinal cord of 5 out of 18 full-term neonates
[40] who died following HIE. Nitrotyrosine forms from
peroxynitrite, a powerful nitrating and oxidising agent that
is the reaction product of NO and superoxide anions. Patho-
logical conditions, such as HI, excessively activate neuronal
and inducible NOS, leading to elevated NO and subsequent
increased peroxynitrite production [19, 41]. This is known
to cause oxidative damage to cellular constituents and trig-
ger cell death [42]. Our results demonstrate that RIPostC
administered immediately after the end of transient global HI
and consisting of 4 cycles of 10-minute hind limb ischemia
followed by 4 cycles of 10-minute reperfusion significantly
reduced the presence of cytoplasmic nitrotyrosine deposits
in the brain 48 hours after HI.The reduction in nitrotyrosine
deposits seen with RIPostC treatment indicates a reduction
in oxidative/nitrosative stress. This is well known to cause
oxidative damage to cellular constituents and trigger cell
death [42]. This suggests that one of the protective effects
of RIPostC is most likely due to a reduction in upstream
production of NO.
4.2. Remote Ischemic Postconditioning Reduces iNOS Expres-
sion. At the onset of ischemia, nNOS is responsible for the
overproduction ofNOand consequent cytotoxicity described
above [8]. iNOS, which is not normally present in healthy tis-
sue, is activated by a number of inflammatory and immuno-
logic signals [43–45] as well as cerebral ischemia. In contrast
to nNOS, iNOS activity peaks in the later stages of ischemic
damage [46], suggesting that the NO it generates contributes
to delayed cell damage. In neonatal encephalopathy it is the
delayed cell death as a result of secondary energy failure
that is correlated with the severity of adverse outcomes [47,
48], and iNOS inhibitors have shown protective effects even
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Figure 4: Colocalization of nitrotyrosine deposits and oxidative stress/neural markers. Nitrotyrosine deposits were mostly visible in neurons
of HI animals (white arrows, (a)), with some colocalization also present in RIPostC-treated piglets (b). This colocalization was also observed
to a much smaller extent in microglia of RIPostC animals (c-d), endothelial cells in the HI group (g-h), and toxic nNOS (i-j) and iNOS (k-l)
for both treatments but not in astroglial (e-f). iNOS double labelling (black box) showed its expression in neurons (m-n) and astrocytes (q-r)
of both HI and RIPostC animals but not in endothelial cells (s-t). iNOS was also expressed by microglia in the RIPostC group (o-p).
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when administered 24 hours after MCA [49]. Whilst in the
current study, nNOS levels were unchanged in the RIPostC
group compared with untreated animals; levels of iNOS were
significantly reduced. In rats, selective inhibition of iNOS
activity with aminoguanidine attenuates postischemic iNOS
activity and reduces infarct volume followingmiddle cerebral
artery occlusion (MCA) [46]. Similarly, iNOS-knockoutmice
do not exhibit ischemia-induced iNOS expression and have
smaller tissue infarction than wild-type mice after MCA
occlusion [50]. Additionally, a study by Wei and colleagues
has shown that ischemic postconditioning attenuated iNOS
and nitrotyrosine production following focal MCA occlusion
[51]. Patients with acute myocardial infarct who underwent
ischemic postconditioning demonstrated reduction in iNOS
activity in white blood cells as well as decreased plasma
nitrotyrosine. The same group showed similar effect in the
rat model of myocardial ischemia/reperfusion injury [28].
This suggests that RIPostC may confer neuroprotection in
our model by reducing iNOS expression and subsequent
production of superoxide to generate peroxynitrite resulting
in nitrotyrosine formation.
4.3. Remote Ischemic Postconditioning Increases eNOS Expres-
sion. In contrast to iNOS and nNOS, eNOS-derived NO
has a functionally protective role. In the brain, eNOS is
expressed in cerebral endothelial cells [52] and acts as a potent
vasodilator; the NO it generates is critical for regulating
vascular tone. This facilitates cerebrovascular perfusion and
protects against ischemic brain damage by improving blood
flow to ischemic tissue [41]. Accordingly, eNOS-knockout
mice have reduced cerebral blood flow and enlarged cerebral
infarcts after stroke [53]. Conversely, upregulation of eNOS
reduces infarct volume after focal [54] and global [55]
cerebral ischemia in rats. In the current study, RIPostC-
treated animals demonstrated significant upregulation of
eNOS expression 48 hours after HI.This is in agreement with
the effect of RIPostC on eNOS expression already reported
by Peng et al., 2012, where the neuroprotective effect of
RIPostC resulted in significant upregulation of eNOS via
the PI3K/Akt pathway. This protective effect was reversed
following the administration of NG-nitro-L-arginine methyl
ester (L-NAME), a NOS inhibitor [17, 55]. Therefore, an
increase in eNOS-derived NO probably mediates some of the
neuroprotective effect of RIPostC demonstrated in our piglet
model of global HI.
4.4. Remote Ischemic Postconditioning Activates Microglia. In
the current study, levels of IBA1 were significantly increased
in RIPostC-treated animals compared to untreated controls.
Depending on the extent of injury microglia are classi-
fied as either classical (M1) or alternative (M2) and exert
neurotoxic or neuroprotective functions, respectively. In
ischemic conditions, M1microglia produce proinflammatory
cytokines, reactive oxygen species, and neurotoxic factors
and destructively phagocytose tissue whereas M2 produce
anti-inflammatory cytokines and neurotrophic factors and
phagocytose dying neurons [56, 57]. Accordingly, selective
ablation of microglia in mice increases infarct size and
apoptosis after stroke [58], but use of microglial inhibitors
provides significant neuroprotection against global ischemia
[59]. This highlights the complexity of the role of microglia-
mediated inflammation in neurological damage or disease.
In the current study we observed a significant increase in
IBA1 immunoreactivity. This is not in concordance with our
previous results, where IBA1 was significantly reduced in
the corpus callosum of RIPostC-treated piglets [29]. This
difference in results may be a consequence of different
analyses, with threshold imaging proving to be a more
thorough assessment encompassing a greater area of the
different assessed brain regions. The current results raise
questions on whether RIPostC treatment is associated with
increase in M2 microglial activation or whether there is a
neuroprotective effect provided by RIPostC despite microglia
activation.
4.5. Remote Ischemic Postconditioning Upregulates Astroglial
Immunoreactivity. GFAP expression was significantly
increased in the RIPostC-treated group. Similarly to NO,
there is evidence of a dual role of astrocyte activation
following HI. Many studies have shown that attenuation
of astrogliosis often correlates with reduced infarct size—
nonspecific inhibition of cell proliferation [60] or inhibition
of astrocyte component synthesis [61] reduce infarct size
accompanied by an attenuated astroglial response. Activated
astrocytes secrete a number of proinflammatory cytokines
and chemokines, responsible for inducing apoptotic cell
death, increasing production of toxic NO, and attracting
inflammatory cells to the injured site [62]. However, astroglia
also support neurons through providing an antioxidant effect,
reducing excitotoxicity and downstream oxidative stress by
taking up excess glutamate, and producing neurotrophic
factors [63] to reduce injury and promote recovery.
Administration of astrocyte-derived factors reduces cerebral
oedema and lesion size in rats with induced focal ischemia
[64]. GFAP-knockout mice exhibit larger lesions and a
greater reduction in cerebral blood flow following focal
cerebral ischemia [65]. This suggests that the increase in
astrocyte activation seen in the current study with RIPostC
treatment could be a contributor to its neuroprotective
effect by assisting with vasogenesis. Interestingly, one of the
mechanisms in which RIPostC is thought to be involved
is the humoral pathway, where circulation of blood-borne
protective factors is released by the ischemic limb as well as
efferent nerve activation [29]. Therefore, it could be possible
that astrocytes may assist with increased blood flow and
activation of prosurvival factors and repair mechanisms. The
current findings on both microglia and astroglial activation
following RIPostC treatment are intriguing and represent a
very interesting avenue for further investigation.
5. Conclusion
In the piglet model of perinatal asphyxia, RIPostC treatment
provided significant white matter protection as observed
through TUNEL assay [29]. In the current study, this
RIPostC-induced neuroprotection appears to be associated
with observed reduced nitrotyrosine deposits across the brain
48 hours after HI.This reductionmay be a result of an overall
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increase in eNOS, as well as reduction of iNOS expression
across all assessed brain regions. This RIPostC-mediated
reduction in nitrosative stress has also been observed in
other in vivo and clinical studies [28, 51, 55]. Interestingly,
we have also shown significant increase in astroglial and
microglia activation not previously observed. This raises
question on whether increased glial activation is somehow
protective or whether RIPostC has a beneficial effect reducing
nitrosative stress irrespective of glial activation. Furthermore,
nitrotyrosine deposits were mostly present in neurons but
were also found to a smaller extent in glial cells. Our findings
demonstrate the need for better understanding the potential
dual role of glial activation following HI. Overall, this study
suggests that the neuroprotective effects previously reported
aremediated, at least in part, by alteration of nitrosative stress
despite glial activation.The effective but safe and noninvasive
nature of RIPostC makes it an attractive potential treatment
for NE.
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